Ventricular fibrillation (VF) is a ventricular arrhythmia characterized by chaotic and disorganized electrical activity that prevents the ventricles from contracting effectively. This condition leads to a complete loss of cardiac output and, if not treated immediately, is fatal. VF is the most common cause of sudden cardiac arrest and requires immediate electrical defibrillation to restore an organized rhythm.
Ventricular fibrillation can be classified into two main types:
Sustained VF: persists until medical intervention and quickly causes loss of consciousness and cardiocirculatory arrest.
Non-sustained VF: short, self-limited episodes that may be asymptomatic or present with transient symptoms, but increase the risk of progression to sustained VF.
VF is one of the most severe cardiac emergencies, and time is critical: without early defibrillation, the likelihood of survival decreases by approximately 7–10% for each minute of delay. If left untreated, it quickly progresses to asystole and sudden cardiac death.
Etiology, Pathogenesis, and Pathophysiology
Ventricular fibrillation is a fatal arrhythmia that can result from several pathological conditions:
Acute myocardial infarction: myocardial necrosis alters electrical conduction and can trigger VF, particularly during the early hours of an infarct.
Myocardial ischemia: reduced oxygen supply to the myocardium, even without necrosis, may cause electrical instability in the ventricles.
Myocarditis: inflammatory processes in the myocardium can disrupt conduction and increase the risk of VF.
Cardiomyopathies: conditions such as dilated cardiomyopathy, hypertrophic cardiomyopathy, and arrhythmogenic right ventricular dysplasia create an unstable electrical substrate that predisposes to VF.
Long and short QT syndromes: congenital abnormalities in ventricular repolarization that can favor the onset of VF.
Brugada syndrome: a genetic conduction disorder that may lead to VF even in the absence of structural heart disease.
Advanced valvular disease: severe aortic stenosis and other valvular conditions may induce ventricular dysfunction and predispose to VF.
Electrocution: a direct electric shock to the chest can cause chaotic myocardial depolarization, triggering VF.
Chest trauma (commotio cordis): a direct blow to the chest during the heart’s vulnerable period may induce VF even in the absence of heart disease.
From a pathogenetic standpoint, ventricular fibrillation occurs when the ventricular myocardium loses its ability to conduct impulses in a coordinated manner. This phenomenon results from two main mechanisms:
Electrical reentry: occurs when an electrical impulse becomes blocked in an ischemic or damaged area of the myocardium and is redirected chaotically, generating multiple reentry circuits that fragment ventricular electrical activity.
Dispersion of repolarization: heterogeneous repolarization across different ventricular regions promotes ectopic impulses and loss of synchronized contraction.
From a pathophysiological perspective, VF causes a complete loss of the heart’s pumping function. The ventricles contract rapidly and ineffectively, preventing proper filling and ejection of blood. This results in immediate cardiac arrest and interruption of blood flow to all vital organs.
If not promptly treated, VF rapidly evolves into asystole and leads to sudden cardiac death within minutes.
Risk Factors and Prevention
Ventricular fibrillation does not always occur spontaneously but is often preceded by conditions that increase the myocardium's susceptibility to ventricular arrhythmias. If identified early, these factors allow for timely intervention before a potentially fatal event occurs.
One of the main predictors of ventricular fibrillation is the presence of pre-existing ventricular arrhythmias. In particular, ventricular flutter can represent a transitional arrhythmia that precedes the onset of VF, especially in patients with structural heart disease or myocardial ischemia.
In addition to pre-existing arrhythmias, several other conditions increase the risk of VF:
Previous cardiac arrest: individuals with a history of VF are at very high risk of recurrence.
Ventricular dysfunction: a reduced ejection fraction (<30%) is strongly associated with malignant ventricular arrhythmias.
Electrolyte imbalances: low potassium and magnesium levels compromise the heart’s electrical stability, favoring arrhythmias.
Pro-arrhythmic drugs: certain antiarrhythmics, antidepressants, and antipsychotics may trigger VF in predisposed individuals.
Substance abuse: cocaine, amphetamines, and other sympathomimetics can cause ventricular electrical instability.
Metabolic and endocrine disorders: diabetes, hypothyroidism, and renal failure can affect ionic balance and cardiac function.
Family history of sudden cardiac death: genetic predisposition is a key factor in susceptibility to ventricular arrhythmias.
Preventive strategies rely on early identification of arrhythmic risk and targeted management of predisposing conditions. In patients with ischemic heart disease, treatment of angina and myocardial revascularization via angioplasty or bypass reduce the risk of VF.
For those affected by inherited arrhythmogenic syndromes, periodic QT interval monitoring and specific medications help prevent fatal events. In high-risk patients, the implantable cardioverter-defibrillator (ICD) is the main strategy to prevent sudden death, thanks to its ability to detect and immediately interrupt VF episodes.
Correcting electrolyte imbalances, discontinuing pro-arrhythmic drugs, and abstaining from stimulant substances are other key preventive measures. Finally, in individuals with a family history of inherited arrhythmias, genetic screening can enable early diagnosis and appropriate risk stratification.
Ventricular fibrillation is a sudden and often fatal event, but proactive management of risk factors and targeted preventive strategies can significantly reduce the risk of occurrence and improve prognosis in predisposed patients.
Clinical Manifestations
Ventricular fibrillation (VF) is a life-threatening arrhythmia that presents with sudden loss of the heart’s pumping function, rapidly leading to hemodynamic collapse and cardiac arrest. In most cases, the onset is abrupt and without warning, but some patients may experience prodromal symptoms suggesting increasing electrical instability of the myocardium.
Prodromal symptoms
Some patients, particularly those with underlying heart disease, may report warning signs before the onset of VF. These symptoms result from unstable ventricular arrhythmias or reduced blood flow to the heart and brain. The most common include:
Palpitations: perception of irregular or rapid heartbeats, often due to ventricular extrasystoles or non-sustained ventricular tachycardia.
Dizziness or lightheadedness: caused by transient cerebral hypoperfusion during episodes of electrical instability.
Chest pain: may precede VF in patients with ischemic heart disease, suggesting acute myocardial ischemia.
Unexplained fatigue: progressive exhaustion related to declining cardiac function.
Dyspnea: reduced cardiac output may lead to pulmonary congestion and shortness of breath.
Syncope or presyncope: the most alarming symptom, indicating compromised cerebral blood flow and often heralding VF onset.
Acute presentation
When a VF episode occurs, prodromal symptoms abruptly disappear and the patient enters a state of cardiocirculatory arrest. The typical clinical features include:
Sudden loss of consciousness: due to lack of cerebral perfusion, occurring within seconds of VF onset.
Absence of pulse: the heart is unable to generate effective contractions, and no arterial pulse is detectable.
Apnea or agonal respiration: irregular breathing, often in the form of gasping, followed by respiratory arrest.
Cyanosis and pallor: signs of tissue hypoxia that worsen rapidly within minutes.
No response to external stimuli: the patient becomes deeply unconscious and unresponsive.
Objective findings
During a VF episode, bystanders or healthcare providers may observe the following clinical signs:
Sudden cardiac arrest: the patient collapses without warning and shows no palpable cardiac activity.
Seizure-like movements: severe cerebral hypoxia may trigger involuntary muscle contractions mimicking seizures.
Mydriasis: dilated pupils due to cerebral hypoperfusion.
Absent blood pressure: no measurable arterial pressure, confirming the lack of cardiac output.
Clinical course
Without immediate intervention, ventricular fibrillation rapidly progresses to asystole, with survival rates decreasing by 7–10% for every minute of defibrillation delay. If not treated, VF inevitably leads to sudden cardiac death.
If the patient is successfully resuscitated, the prognosis depends on several factors, including time to defibrillation, the underlying cause of VF, and the presence of post-arrest neurological damage.
Timeliness of intervention is therefore the most critical factor for patient survival and functional recovery.
Diagnosis
The diagnosis of ventricular fibrillation (VF) is primarily clinical and electrocardiographic. Given the sudden and fatal nature of this arrhythmia, immediate recognition is essential to initiate resuscitation and defibrillation efforts. VF should be suspected in any patient with sudden loss of consciousness, absence of pulse and respiration, and confirmed through electrocardiogram (ECG).
Electrocardiogram
The ECG is the key tool for diagnosing VF and shows a characteristic pattern with:
Chaotic and disorganized electrical activity: absence of discernible P waves, QRS complexes, and T waves.
Rapid and irregular oscillations: varying amplitude and frequency in an unpredictable pattern.
No repetitive morphology: unlike other ventricular tachyarrhythmias, VF lacks a structured pattern.
Two main types of ventricular fibrillation can be distinguished:
Coarse VF: large-amplitude waves, typically seen in early stages and more responsive to defibrillation.
Fine VF: low-amplitude waves, often a prelude to asystole if not promptly treated.
Differential diagnosis
VF must be distinguished from other causes of cardiac arrest and from ventricular arrhythmias that may respond to medications or synchronized cardioversion. Key conditions to consider include:
Pulseless ventricular tachycardia: shows more organized electrical activity than VF and may respond to antiarrhythmic drugs.
Asystole: total absence of electrical activity. Differentiating fine VF from asystole is crucial to avoid inappropriate treatment.
Motion artifacts: tremors or movement during transport may generate ECG tracings that mimic VF.
Role of continuous monitoring
In at-risk patients, continuous ECG monitoring in the intensive care unit or cardiology ward allows for early detection of VF episodes and timely intervention. In patients with long QT syndrome, Brugada syndrome, or arrhythmogenic right ventricular dysplasia, continuous monitoring is vital to prevent fatal events.
Post-resuscitation investigations
If the patient survives a VF episode, thorough diagnostic evaluation is required to identify the underlying cause and prevent recurrence. These investigations include:
Echocardiogram: to assess ventricular function and detect structural heart disease.
Coronary angiography: indicated in patients with suspected myocardial ischemia.
Genetic testing: for suspected inherited arrhythmias (e.g., long QT, Brugada, arrhythmogenic dysplasia).
Electrolyte panel: to identify imbalances that may have triggered the VF episode.
Holter ECG: to monitor for ventricular arrhythmias in the post-resuscitation period.
A comprehensive diagnostic approach is essential to determine the cause of VF and avoid fatal recurrences.
Treatment and Prognosis
Ventricular fibrillation (VF) is a true medical emergency that requires immediate intervention. Treatment is based on early defibrillation, supported by cardiopulmonary resuscitation (CPR) and strategies to prevent recurrence. Every minute of delay in defibrillation reduces the probability of survival by 7–10%.
Acute treatment
The management of VF follows the advanced cardiac life support (ACLS) protocol:
Early defibrillation: the cornerstone of treatment. The shock synchronizes myocardial activity and interrupts VF. The first shock should be delivered as soon as possible using a biphasic defibrillator at 200–360 J.
Cardiopulmonary resuscitation (CPR): if the first shock fails, high-quality chest compressions (100–120/min) are initiated, alternating with ventilation at a 30:2 ratio.
Drug administration: after the second shock, epinephrine (1 mg every 3–5 minutes) is administered to support cerebral perfusion. If VF persists, amiodarone (300 mg bolus, followed by 150 mg if needed) or lidocaine may be used.
Treatment of reversible causes: identifying and correcting hypoxia, acidosis, hypothermia, and electrolyte imbalances increases the chances of restoring spontaneous circulation.
Post-resuscitation management
If the patient survives VF, it is crucial to stabilize hemodynamics and identify the underlying cause:
Intensive monitoring: admission to intensive care with continuous ECG monitoring is mandatory.
Correction of precipitating factors: management of myocardial ischemia, electrolyte disturbances, and other triggers is essential.
Neurological evaluation: anoxic brain injury is a major concern after prolonged resuscitation.
Therapeutic hypothermia: in comatose post-arrest patients, targeted temperature management (32–36°C for 24 hours) reduces neurological damage.
Prevention of recurrence
Long-term prevention depends on the event’s etiology and risk stratification:
Implantable cardioverter-defibrillator (ICD): indicated for patients with reduced ejection fraction (<35%) or VF without reversible causes, it is the most effective measure to prevent sudden death.
Antiarrhythmic drugs: amiodarone or beta-blockers are used to reduce the risk of future arrhythmias.
Treatment of ischemic heart disease: in cases of VF secondary to myocardial infarction, coronary revascularization through angioplasty or bypass is essential.
Prognosis
The prognosis of ventricular fibrillation depends on the promptness of intervention:
If defibrillation occurs within 3–5 minutes, survival rates may exceed 50%.
If treatment is delayed beyond 10 minutes, survival drops to 5–10%, with a high risk of irreversible brain damage.
Recurrence prevention and long-term monitoring are crucial to improve survival and reduce the risk of future VF episodes.
Complications
Ventricular fibrillation is fatal if not treated immediately. Even in successfully resuscitated patients, numerous complications may arise, impacting long-term prognosis. The main complications stem from the prolonged absence of perfusion during the episode and the resuscitation procedures themselves.
Post-anoxic brain injury
Lack of cerebral blood flow for more than 4–5 minutes can cause cerebral ischemia and variable degrees of neurological damage:
Cognitive deficits: including memory, attention, and concentration impairment.
Post-anoxic hypoxic encephalopathy: in severe cases, permanent neurological disability may develop.
Vegetative state or brain death: occurs when anoxia lasts more than 10–15 minutes without circulatory restoration.
Therapeutic hypothermia initiated within the first 6 hours post-resuscitation can reduce neurological damage in comatose patients.
Post-cardiac arrest syndrome
Following return of spontaneous circulation, a systemic inflammatory response similar to sepsis may occur, characterized by:
Multiorgan dysfunction: persistent hypoperfusion affecting the kidneys, liver, and lungs.
Cardiogenic shock: in patients with severely reduced ejection fraction, cardiac function remains impaired.
Pulmonary edema: secondary to post-arrest left ventricular dysfunction.
Recurrent arrhythmias
Resuscitated patients remain at high risk for new VF episodes, especially if the underlying cause is not addressed. Recurrences may occur due to:
Persistent myocardial ischemia: if no revascularization is performed, VF may recur.
Uncorrected electrolyte disturbances: hypokalemia and hypomagnesemia predispose to further arrhythmic events.
Absence of ICD protection: high-risk patients without a defibrillator are more likely to experience sudden death.
Resuscitation-related injuries
Although lifesaving, CPR may cause physical injuries:
Rib and sternal fractures: commonly seen after effective chest compressions.
Pneumothorax: rib fractures may puncture the pleura, causing lung collapse.
Pulmonary lacerations: may result from overly aggressive ventilation.
Post-arrest heart failure
In some patients, VF causes permanent damage to ventricular function, leading to:
Reduced ejection fraction: indicator of persistent ventricular dysfunction.
Post-arrest cardiomyopathy: irreversible myocardial injury may result in chronic heart failure.
Long-term prognosis
The prognosis of patients who survive VF depends on the timeliness of intervention and pre-existing conditions:
If defibrillated within 3–5 minutes, neurological and cardiac recovery is generally favorable.
If resuscitation occurs after 10 minutes, the risk of permanent brain damage is high.
If VF is secondary to a reversible condition, the recurrence risk is low once the cause is addressed.
Close monitoring and preventive strategies, such as ICD implantation in high-risk patients, can significantly reduce mortality and improve long-term quality of life.
References
Priori SG, Blomström-Lundqvist C, Mazzanti A, et al. ESC Guidelines for the Management of Patients with Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death.European Heart Journal. 2015.
Roden DM. Predicting drug-induced QT prolongation and torsades de pointes.J Physiol. 2016.
Gorgels AP, Gijsbers C, de Vreede-Swagemakers J, et al. Out-of-Hospital Cardiac Arrest—The Importance of the First Link in the Chain of Survival.Resuscitation. 2003.
Neumar RW, Nolan JP, Adrie C, et al. Post–Cardiac Arrest Syndrome: Epidemiology, Pathophysiology, Treatment, and Prognostication.Circulation. 2008.
Kushner FG, Hand M, Smith SC Jr, et al. 2010 Focused Updates: Guidelines for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care.Circulation. 2010.
Chen-Scarabelli C, Scarabelli TM. Neurocardiology of Sudden Cardiac Death.J Am Coll Cardiol. 2006.
Aliot EM, Stevenson WG, Almendral-Garrote JM, et al. Prevention of Sudden Cardiac Death Due to Ventricular Arrhythmias.Eur Heart J. 2001.
Goldberger JJ, Cain ME, Hohnloser SH, et al. American Heart Association/American College of Cardiology Foundation/Heart Rhythm Society Scientific Statement on Risk Stratification for Sudden Cardiac Death.Circulation. 2008.
Myerburg RJ, Reddy V, Castellanos A. Mechanisms of Sudden Cardiac Death: From the Cellular Level to the Population.Am J Med. 2006.
